Matrix metalloproteinase 9 expression is induced by Epstein-Barr virus latent membrane protein 1 C-terminal activation regions 1 and 2

Journal of Virology

Volumn 73, Issue 7, 1999, Pages 5548-5555

  Takeshita, Hajime ^a,b   Yoshizaki, Tomokazu ^a,b   Miller, William E ^a   Sato, Hiroshi ^b   Furukawa, Mitsuru ^b   Pagano, Joseph S ^a   Raab Traub, Nancy ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b KANAZAWA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; GELATINASE B; LATENT MEMBRANE PROTEIN 1; MATRIX METALLOPROTEINASE; MUTANT PROTEIN; ONCOPROTEIN; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BASEMENT MEMBRANE; CARBOXY TERMINAL SEQUENCE; ENZYME ACTIVITY; EPSTEIN BARR VIRUS; GENE ACTIVATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; NASOPHARYNX CANCER; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; VIRUS ACTIVATION; VIRUS CARCINOGENESIS;

EID: 0033031799     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.73.7.5548-5555.1999     Document Type: Article

References (60)

1. Akiba, H., H. Nakano, S. Nishikawa, M. Shindo, T. Kobata, M. Atsuta, C. Morimoto, C. F. Ware, N. L. Malinin, D. Wallach, H. Yagita, and K. Okumura. 1998. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF-2, TRAF-5, and NF-kappaB-inducing kinase. J. Biol. Chem. 273:13353-13358.
2. Bernhard, E. J., S. T. Gruber, and R. J. Muschel. 1994. Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl. Acad. Sci. USA 91:4293-4297.
3. Brooks, L., Q. Y. Yao, A. B. Rickinson, and L. S. Young. 1992. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA-1, LMP-1, and LMP-2 transcripts. J. Virol. 66:2689-2697.
4. Chen, M. L., C. N. Tsai, C. L. Liang, C. H. Shu, C. R. Huang, D. Sulitzeanu, S. T. Liu, and Y. S. Chang. 1992. Cloning and characterization of the latent membrane protein (LMP) of a specific Epstein-Barr virus variant derived from the nasopharyngeal carcinoma in the Taiwanese population. Oncogene 7:2131-2140.
5. Chow, D. 1994. Image densitometric analysis, p. 1-23. In D. Chow (ed.), NIH Image 1.54: using image for densitometric analysis of 1-D gels. National Institutes of Health, Bethesda, Md.
6. Devergne, O., E. Hatzivassiliou, K. M. Izumi, K. M. Kaye, E. Kieff, and G. Mosialos. 1996. Association of TRAF-1, TRAF-2, and TRAF-3 with an Epstein-Barr virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation. Mol. Cell Biol. 16:7098-7108.
7. Docherty, A. J., J. O'Connell, T. Crabbe, S. Angal, and G. Murphy. 1992. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. Trends Biotechnol. 10:200-207.
8. Eliopoulos, A. G., M. Stack, C. W. Dawson, K. M. Kaye, L. Hodgkin, S. Sihota, M. Rowe, and L. S. Young. 1997. Epstein-Barr virus LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 14:2899-2916.
9. Eliopoulos, A. G., and L. S. Young. 1998. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP-1). Oncogene 16:1731-1742.
10. Fennewald, S., V. van Santen, and E. Kieff. 1984. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J. Virol. 51:411-419.
11. Floettmann, J. E., and M. Rowe. 1997. Epstein-Barr virus latent membrane protein-1 (LMP-1) C-terminus activation region 2 (CTAR-2) maps to the far C-terminus and requires oligomerisation for NF-kappaB activation. Oncogene 15:1851-1858.
12. Hatzivassiliou, E., W. E. Miller, N. Raab-Traub, E. Kieff, and G. Mosialos. 1998. A fusion of the EBV latent membrane protein-1 (LMP1) transmembrane domains to the CD40 cytoplasmic domain is similar to LMP1 in constitutive activation of epidermal growth factor receptor expression, nuclear factor-kappa B, and stress-activated protein kinase. J. Immunol. 160: 1116-1121.
13. Hua, J., and R. J. Muschel. 1996. Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. 56:5279-5284.
14. Huen, D. S., S. A. Henderson, D. Croom-Carter, and M. Rowe. 1995. The Epstein-Barr virus latent membrane protein-1 (LMP-1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10:549-560.
15. Huhtala, P., L. T. Chow, and K. Tryggvason. 1990. Structure of the human type IV collagenase gene. J. Biol. Chem. 265:11077-11082.
16. Huhtala, P., A. Tuuttila, L. T. Chow, J. Lohi, J. Keski-Oja, and K. Tryggvason. 1991. Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. J. Biol. Chem. 266:16485-16490.
17. Ito, C. Y., A. G. Kazantsev, and A. S. Baldwin, Jr. 1994. Three NF-kappa B sites in the I kappa B-alpha promoter are required for induction of gene expression by TNF alpha. Nucleic Acids Res. 22:3787-3792.
18. Itoh, Y. 1998. Degradation of extracellular matrix in cancer; activation of MMPs promotes cancer cell invasion and metastasis. Cell Technol. 17:523-533.
19. Izumi, K. M., and E. D. Kieff. 1997. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc. Natl. Acad. Sci. USA 94:12592-12597.
20. Karin, M., and M. Delhase. 1998. JNK or IKK, AP-1 or NF-kappaB, which are the targets for MEK kinase 1 action? Proc. Natl. Acad. Sci. USA 95: 9067-9069.
21. Kaye, K. M., K. M. Izumi, and E. Kieff. 1993. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA 90:9150-9154.
22. Kaye, K. M., O. Devergne, J. N. Harada, K. M. Izumi, R. Yalamanchili, E. Kieff, and G. Mosialos. 1996. Tumor necrosis factor receptor associated factor 2 is a mediator of NF-kappa B activation by latent infection membrane protein 1, the Epstein-Barr virus transforming protein. Proc. Natl. Acad. Sci. USA 93:11085-11090.
23. Kieff, E. 1996. Epstein-Barr virus and its replication, p. 2343-2396. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
24. Kieser, A., E. Kilger, O. Gires, M. Ueffing, W. Kolch, and W. Hammerschmidt 1997. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 16:6478-6485.
25. Klein, G. 1994. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77:791-793.
26. Liotta, L. A., C. N. Rao, and U. N. Wewer. 1986. Biochemical interactions of tumor cells with the basement membrane. Annu. Rev. Biochem. 55:1037-1057.
27. Liotta, L. A., P. S. Steeg, and W. G. Stetler-Stevenson. 1991. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 64:327-336.
28. Liotta, L. A. 1986. Tumor invasion and metastases - role of the extracellular matrix: Rhoads Memorial Award lecture. Cancer Res. 46:1-7.
29. Liu, Z. G., H. Hsu, D. V. Goeddel, and M. Karin. 1996. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell 87:565-576.
30. Marsters, S. A., T. M. Ayres, M. Skubatch, C. L. Gray, M. Rothe, and A. Ashkenzaki. 1997. Herpesvirus entry mediator, a member of the tumor necrosis factor receptor (TNFR) family, interacts with members of the TNFR-associated factor family and activates the transcription factors NF-kappaB and AP-1. J. Biol. Chem. 272:14029-14032.
31. Matrisian, L. M. 1990. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet. 6:121-125.
32. Matrisian, L. M. 1992. The matrix-degrading metalloproteinases. Bioessays 14:455-463.
33. Mayo, M. W., C. Y. Wang, P. C. Cogswell, K. S. Roger-Graham, S. W. Lowe, C. J. Der, and A. S. Baldwin, Jr. 1997. Requirement of NF-κB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 278: 1812-1815.
34. Miller, W. E., G. Mosialos, E. Kieff, and N. Raab-Traub. 1997. Epstein-Barr virus LMP1 induction of epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-κB activation. J. Virol. 71:586-594.
35. Miller, W. E., J. L. Cheshire, A. S. Baldwin, Jr., and N. Raab-Traub. 1998. The NPC derived C15 LMP1 protein confers enhanced activation of NF-κB and induction of the EGFR in epithelial cells. Oncogene 16:1869-1877.
36. Miller, W. E., J. L. Cheshire, and N. Raab-Traub. 1998. Interaction of tumor necrosis factor receptor-associated factor signaling proteins with the latent membrane protein 1 PXQXT motif is essential for induction of epidermal growth factor receptor expression. Mol. Cell Biol. 18:2835-2844.
37. Mitchell, T., and B. Sugden. 1995. Stimulation of NF-κB-mediated transcription by mutant derivatives of the latent membrane protein of Epstein-Barr virus. J. Virol. 69:2968-2976.
38. Moorthy, R. K., and D. A. Thorley-Lawson. 1993. All three domains of the Epstein-Barr virus-encoded latent membrane protein LMP-1 are required for transformation of Rat-1 fibroblasts. J. Virol. 67:1638-1646.
39. Moscatelli, D., and D. B. Rifkin. 1988. Membrane and matrix localization of proteinases: a common theme in tumor cell invasion and angiogenesis. Biochim. Biophys. Acta 948:67-85.
40. Nakajima, M., O. Welch, P. N. Belloni, and G. L. Nicholson. 1987. Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. Cancer Res. 47:4869-4876.
41. Natoli, G., A. Costanzo, A. Ianni, D. J. Templeton, J. R. Woodgett, C. Balsano, and M. Levrero. 1997. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. Science 275:200-203.
42. Netzel-Arnett, S., Q. X. Sang, W. G. Moore, M. Navre, H. Birkedal-Hansen, and H. E. Van Wart. 1993. Comparative sequence specificities of human 72-and 92-kDa gelatinases (type IV collagenases) and PUMP (matrilysin). Biochemistry 32:6427-6432.
43. Osborn, L., S. Kunkel, and G. J. Nabel. 1989. Tumor necrosis factor a and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor kB. Proc. Natl. Acad. Sci. USA 86:2336-2340.
44. Pathmanathan, R., U. Prasad, R. Sadler, K. Flynn, and N. Raab-Traub. 1995. Clonal proliferations of cells infected with Epstein-Barr virus in pre-invasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333: 693-698.
45. Pauli, B. U., D. E. Schwartz, E. J. Thonar, and K. E. Kuettner. 1983. Tumor invasion and host extracellular matrix. Cancer Metastasis Rev. 2:129-152.
46. Raab-Traub, N., K. Flynn, G. Pearson, A. Huang, P. Levine, A. Lanier, and J. Pagano. 1987. The differentiated form of nasopharyngeal carcinoma contains Epstein-Barr virus DNA. Int. J. Cancer 39:25-29.
47. Reinhard, C., B. Shamoon, V. Shyamala, and L. T. Williams. 1997. Tumor necrosis factor aα-induced activation of c-jun N-terminal kinase is mediated by TRAF2. EMBO J. 16:1080-1092.
48. Relaix, F., X. J. Wei, X. Wu, and D. A. Sassoon. 1998. Peg3/Pw1 is an imprinted gene involved in the TNF-NFkappaB signal transduction pathway. Nat. Genet. 18:287-291.
49. Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa.
50. Sandberg, M., W. Hammerschmidt, and B. Sugden. 1997. Characterization of LMP-1's association with TRAF-1, TRAF-2, and TRAF-3. J. Virol. 71: 4649-4656.
51. Sato, H., T. Takino, Y. Okada, J. Cao, A. Shinagawa, E. Yamamoto, and M. Seiki. 1994. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 370:61-65.
52. Sato, H., Y. Kida, M. Mai, Y. Endo, T. Sasaki, J. Tanaka, and M. Seiki. 1992. Expression of genes encoding type IV collagen-degrading metalloproteinases and tissue inhibitors of metalloproteinases in various human tumor cells. Oncogene 7:77-83.
53. Sato, H., and M. Seiki. 1993. Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene 8:395-405.
54. Scheinman, R. I., P. C. Cogswell, A. K. Lofquist, and A. S. Baldwin, Jr. 1995. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 270:283-286.
55. Sehgal, G., J. Hua, E. J. Bernhard, I. Sehgal, T. C. Thompson, and R. J. Muschel. 1998. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am. J. Pathol. 152: 591-596.
56. Stearns, M. E., K. Fudge, F. Garcia, and M. Wang. 1997. IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis 17:62-74.
57. Sugihara, Y., H. Shimada, R. C. Seeger, W. E. Laug, and Y. A. DeClerck. 1998. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 58:2209-2216.
58. Takino, T., H. Sato, A. Shinagawa, and M. Seiki. 1995. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J. Biol. Chem. 270:23013-23020.
59. Yoshizaki, T., H. Sato, M. Furukawa, and J. S. Pagano. 1998. The expression of matrix metalloproteinase 9 is enhanced by Epstein-Barr virus latent membrane protein 1. Proc. Natl. Acad. Sci. USA 95:3621-3626.
60. Young, L., C. Alfieri, K. Hennessy, H. Evans, C. O'Hara, K. C. Anderson, J. Ritz, R. S. Shapiro, A. Rickinson, E. Kieff, and J. I. Cohen. 1989. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321:1080-1085.